Baxfendy Tablet, Film Coated
Product Images NDC 0310-6002

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Baxfendy (NDC 0310-6002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1mg_30count_bottle_label (1mg 30count Bottle Label)

This text appears to be a combination of random characters and incomplete information, making it difficult to generate a meaningful description.*

FDA Label Image

2mg_30_count_bottle_label (2mg 30 Count Bottle Label)

FDA Label Image

Figure_1 (Figure 1)

This data compares the change from Baseline in Seated SBP (systolic blood pressure) in patients over multiple weeks (Week 4, 8, and 12) between different treatment groups: Baxdrostat 2mg, Baxdrostat 1mg, and Placebo. The number of patients in each group at each time point is provided. This information can be used to analyze the effectiveness of the different treatments on blood pressure management.*

FDA Label Image

Baxdrostat_structural_formula (Baxdrostat Structural Formula)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.